Cerus to Participate in Gates Foundation-Funded Effort to Support Ebola-Affected Countries

  Cerus’ INTERCEPT Blood System for plasma will be included as part of a Gates Foundation-funded effort to produce and evaluate convalescent plasma as a potential therapy for people infected with Ebola.  
more information


Cerus Corporation is a biomedical products company focused in the field of blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, the INTERCEPT platelet and plasma systems have received FDA approval. The INTERCEPT red blood cell system is in clinical development.

  • Global Headquarters

  • 2550 Stanwell Drive
    Concord, CA US 94520
    +1 925.288.6000
  • European Headquarters

  • Stationsstraat 79-D
    3811 MH Amersfoort, Netherlands
    +31 (0) 33 49 60 600